High-Yield Antiepileptic Drug Comparison
Choosing an antiepileptic drug (AED) depends on seizure type, side-effect profile, drug interactions, and the patient population — especially women of childbearing potential. The master framework divides AEDs into broad-spectrum agents (effective across focal and all generalized seizure types) and narrower-spectrum agents such as carbamazepine and phenytoin, which are effective for focal AND generalized tonic-clonic seizures but can WORSEN generalized absence and myoclonic seizures. This review compares the highest-yield AEDs across mechanism, spectrum, key toxicities, interactions, and use in pregnancy and other special populations.
Levetiracetam — the versatile first-line broad-spectrum agent
Levetiracetam works by binding the SV2A synaptic vesicle protein and is broad-spectrum, effective for both focal and generalized seizures. It is renally cleared with minimal drug interactions, making it especially useful in patients on multiple medications and in the elderly. Its signature adverse effects are behavioral and psychiatric — irritability, mood changes, and behavioral issues. It is a good first-line choice, including for generalized syndromes such as juvenile myoclonic epilepsy, and — along with lamotrigine — is among the lower-risk (preferred) AEDs in pregnancy rather than being unconditionally 'safe.'
Valproic Acid — most effective for generalized, but the teratogen to avoid
Valproic acid has multiple mechanisms (sodium channel effects and GABA enhancement) and is broad-spectrum, being especially effective for generalized epilepsies. However, it carries a heavy toxicity burden: teratogenicity, weight gain, tremor, hepatotoxicity, and pancreatitis. It inhibits CYP450 and raises lamotrigine levels — a critical interaction. Because it has the highest teratogenic risk of the AEDs, it should be AVOIDED in women of childbearing potential whenever possible.
Lamotrigine — broad-spectrum, but titrate slowly to avoid SJS
Lamotrigine blocks sodium channels and is broad-spectrum (focal and generalized). Its defining hazard is Stevens-Johnson syndrome, which is why slow titration is essential. Its levels are decreased by enzyme inducers and increased by valproate — so the dose must be adjusted when combined with valproate. Along with levetiracetam, it is among the lower-risk, preferred agents in pregnancy, but the slow titration requirement must always be respected.
Carbamazepine — effective for focal and generalized tonic-clonic seizures, but worsens absence/myoclonic
Carbamazepine blocks sodium channels and is effective for focal seizures and for generalized tonic-clonic seizures. Its key side effects are hyponatremia, blood dyscrasias, rash, and diplopia. It is a potent CYP450 inducer and reduces oral contraceptive efficacy. Critically, it should be AVOIDED when absence or myoclonic seizures are present because it worsens (exacerbates) these seizure types — a common pitfall when generalized syndromes such as JME are mistaken for focal epilepsy.
Phenytoin — sodium-channel blocker, zero-order kinetics, cosmetic and metabolic toxicities
Phenytoin blocks sodium channels and is effective for focal seizures and for generalized tonic-clonic seizures. Its cosmetic toxicities are gingival hyperplasia, hirsutism, and coarsening of facial features; nystagmus and ataxia reflect dose-related neurotoxicity. Separately, chronic use causes a metabolic bone toxicity — osteoporosis/osteomalacia from CYP450 induction that accelerates vitamin D metabolism. It is a potent CYP450 inducer and follows zero-order kinetics, so small dose increases can cause disproportionate rises in level. It is teratogenic and, like carbamazepine, can worsen absence and myoclonic seizures, so it should be avoided when those seizure types are present.
Ethosuximide — the absence-only specialist
Ethosuximide blocks T-type calcium channels and is narrow in a different sense — it is effective for absence seizures ONLY. Side effects are relatively mild: GI upset, headache, and drowsiness, with minimal drug interactions. It is first-line for childhood absence epilepsy.
Special Populations — pregnancy and the elderly
All AEDs carry some teratogenic risk. Valproate has the highest risk and should be avoided if possible; lamotrigine and levetiracetam are the lower-risk, preferred agents in pregnancy. High-dose folate supplementation is recommended, and AED levels often drop during pregnancy, requiring monitoring. In the elderly, start low and go slow, avoid heavily sedating agents, and consider drug interactions — levetiracetam and lamotrigine are often preferred here as well.
High-yield
- Broad-spectrum AEDs (levetiracetam, valproic acid, lamotrigine) cover focal and all generalized seizure types; carbamazepine and phenytoin treat focal and generalized tonic-clonic seizures but can worsen absence and myoclonic seizures.
- Valproate has the highest teratogenic risk — avoid in women of childbearing potential.
- Lamotrigine and levetiracetam are the lower-risk, preferred AEDs in pregnancy.
- Valproate inhibits CYP450 and raises lamotrigine levels; carbamazepine and phenytoin are potent CYP450 inducers.
- Carbamazepine reduces oral contraceptive efficacy (enzyme induction).
- Lamotrigine requires slow titration to prevent Stevens-Johnson syndrome.
- Phenytoin follows zero-order kinetics — small dose changes cause large level changes.
- Phenytoin cosmetic toxicities = gingival hyperplasia, hirsutism, coarse facies; osteoporosis is a separate metabolic/bone toxicity from enzyme induction and altered vitamin D metabolism.
- Ethosuximide (T-type Ca2+ channel blocker) is first-line for childhood absence epilepsy.
- Levetiracetam acts on SV2A, is renally cleared, and has minimal drug interactions but causes behavioral/mood side effects.
- Carbamazepine and phenytoin worsen (exacerbate) absence and myoclonic seizures — do not use in syndromes with those seizure types, such as JME.
- Levetiracetam and lamotrigine are preferred in the elderly (fewer interactions, less sedation).
Pitfalls
- Treating a syndrome with absence or myoclonic seizures (e.g., JME) with carbamazepine or phenytoin — although these drugs work for focal and generalized tonic-clonic seizures, they worsen absence and myoclonic seizures.
- Forgetting that valproate raises lamotrigine levels — the lamotrigine dose must be reduced when combined, and titration must be even slower to avoid SJS.
- Titrating lamotrigine too quickly and precipitating Stevens-Johnson syndrome.
- Overlooking that carbamazepine and phenytoin induce CYP450 and reduce efficacy of oral contraceptives and other drugs.
- Assuming linear kinetics with phenytoin — its zero-order kinetics mean small dose increases can cause toxicity.
- Miscategorizing phenytoin's osteoporosis as a cosmetic effect — it is a metabolic bone complication of enzyme induction, distinct from gingival hyperplasia and hirsutism.
- Using valproate in a woman of childbearing potential when lower-risk broad-spectrum options (lamotrigine, levetiracetam) exist.
- Expecting ethosuximide to cover generalized tonic-clonic or focal seizures — it is for absence seizures only.
- Assuming carbamazepine and phenytoin are 'focal only' — they are also effective for primary generalized tonic-clonic seizures; their limitation is specifically absence and myoclonic seizures.
- Missing carbamazepine-induced hyponatremia or blood dyscrasias during monitoring.
- Overstating levetiracetam as unconditionally 'safe' in pregnancy — it is one of the lower-risk, preferred options, not risk-free.
Clinical pearls
- "Dropping the coffee cup at breakfast" JME points to broad-spectrum therapy (levetiracetam or lamotrigine); never carbamazepine.
- In a pregnant patient with epilepsy, reach for lamotrigine or levetiracetam and supplement folate.
- Gingival hyperplasia + hirsutism + nystagmus = phenytoin toxicity.
- A new rash in a patient recently started on lamotrigine — think Stevens-Johnson syndrome and stop the drug.
- Hyponatremia in an epileptic on a sodium-channel blocker suggests carbamazepine.
- Behavioral changes and irritability in a well-controlled patient on a renally cleared AED point to levetiracetam.
- Chronic phenytoin causing low vitamin D and weak bones reflects enzyme induction — a metabolic, not cosmetic, effect.
Frequently asked
Which AEDs are broad-spectrum, and how do carbamazepine and phenytoin differ, and why does it matter?
Broad-spectrum agents (levetiracetam, valproic acid, lamotrigine) treat focal and all generalized seizure types. Carbamazepine and phenytoin are effective for focal AND generalized tonic-clonic seizures, but they can WORSEN generalized absence and myoclonic seizures — so they should not be used in syndromes with those seizure types (e.g., JME). Ethosuximide is narrow in that it treats absence seizures only.
Which AED should be avoided in women of childbearing potential?
Valproic acid — it has the highest teratogenic risk. Lamotrigine and levetiracetam are the lower-risk, preferred options in pregnancy, along with high-dose folate supplementation and level monitoring, since AED levels often drop during pregnancy.
Why does lamotrigine require slow titration?
To avoid Stevens-Johnson syndrome. Titration must be even more cautious when combined with valproate, because valproate raises lamotrigine levels.
What is the significance of phenytoin's zero-order kinetics?
At therapeutic concentrations, phenytoin is eliminated at a fixed rate, so small dose increases can produce disproportionately large — and potentially toxic — rises in serum level. It is also a potent CYP450 inducer and teratogenic.
Are phenytoin's toxicities all cosmetic?
No. Gingival hyperplasia, hirsutism, and coarsening of facial features are the cosmetic effects. Osteoporosis/osteomalacia is a separate metabolic bone toxicity driven by CYP450 induction that accelerates vitamin D breakdown; nystagmus and ataxia are dose-related neurotoxic effects.
Why should carbamazepine not be used in JME?
Although carbamazepine is effective for focal and generalized tonic-clonic seizures, it worsens absence and myoclonic seizures. Because JME features myoclonic (and often absence) seizures, carbamazepine exacerbates them. JME is frequently misdiagnosed as focal epilepsy and wrongly treated with carbamazepine, which makes seizures worse.
What is the first-line drug for childhood absence epilepsy?
Ethosuximide, which blocks T-type calcium channels. It is effective for absence seizures only, with relatively mild side effects (GI upset, headache, drowsiness) and minimal drug interactions.
How do AED drug interactions differ across these agents?
Valproate inhibits CYP450 and raises lamotrigine levels. Carbamazepine and phenytoin are potent CYP450 inducers — carbamazepine also reduces oral contraceptive efficacy, and inducers lower lamotrigine levels. Levetiracetam and ethosuximide have minimal interactions; levetiracetam is renally cleared.
Turn this into reasoning you can use on exam day — practice High-Yield Antiepileptic Drug Comparison on branching cases where your decisions shape the patient.